stockmarketproxy
/
ZTSNYSE SEC EDGAR

Zoetis Inc.

Pharmaceutical Preparations·PARSIPPANY, NJ·FY end 12/31·CIK 1555280
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$9.5B$9.3B$8.5B$8.1B$7.8B
Gross Profit——————
Operating Income——————
Net Income$2.7B$2.5B$2.3B$2.1B$2.0B
Operating CF$2.9B$3.0B$2.4B$1.9B$2.2B
Capex$621.0M$655.0M$732.0M$586.0M$477.0M
Free Cash Flow$2.3B$2.3B$1.6B$1.3B$1.7B
Buybacks$248.0M$1.9B$1.1B$1.6B$743.0M
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin28.2%26.9%27.4%26.2%26.2%
FCF Margin24.1%24.8%19.0%16.4%22.3%
R&D / Revenue——————
Effective Tax20.4%20.3%20.3%20.5%18.2%
Debt / Equity2.711.091.311.491.45
Buybacks / FCF10.9%80.9%67.4%120.2%42.8%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
ZTS
236:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
ZTS
—
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
ZTS
28.2%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%